临床因素与胰腺导管腺癌术前治疗后主要病理缓解的关联
该回顾性研究纳入583例接受术前治疗并胰腺切除术的胰腺导管腺癌患者,发现13.2%出现主要病理缓解,主要缓解者中位总生存显著延长(73.4个月 vs 32.2个月,P < .001)。多因素分析显示仅年龄小于50岁、基线CA19-9低于200 U/mL和吉西他滨作为放疗增敏剂与主要缓解相关。
要点
- 主要病理缓解(<5%存活癌细胞)与显著延长的总生存相关。
- 年龄<50岁、基线CA19-9<200 U/mL、吉西他滨作为放疗增敏剂与主要缓解独立相关。
- 具备上述因素数量越多,主要缓解率呈阶梯式上升(0个7.5%,1个12.7%,2个16.9%,3个35.7%,P = .009)。
核心结论
- 主要病理缓解在胰腺导管腺癌术前治疗后不常见,但与显著改善的预后相关。
- 仅年轻年龄、低基线CA19-9和吉西他滨作为放疗增敏剂与主要病理缓解相关。
研究设计与样本
- 回顾性分析德克萨斯大学MD安德森癌症中心前瞻性维护数据库。
- 纳入1990至2015年间接受术前治疗后行胰腺切除术的583例病理确诊胰腺导管腺癌患者。
- 术前治疗包括单纯全身化疗(n=38,6.5%)、单纯放化疗(n=261,44.8%)或两者联合(n=284,48.7%)。
- 手术方式包括胰十二指肠切除术(n=514,88.2%)、远端胰腺切除术(n=62,10.6%)和全胰腺切除术(n=7,1.2%)。
主要发现
- 77例(13.2%)出现主要病理缓解,其中23例(3.9%)为完全病理缓解。
- 主要缓解者中位总生存为73.4个月,非主要缓解者为32.2个月(P < .001)。
- 多因素logistic回归显示年龄<50岁、基线CA19-9<200 U/mL和吉西他滨作为放疗增敏剂与主要缓解相关。
- 阳性因素数量与主要缓解可能性呈阶梯式关联:0个7.5%,1个12.7%,2个16.9%,3个35.7%(P = .009)。
关键数值与推荐
- 主要病理缓解定义为病理完全缓解或残留癌细胞<5%。
- 主要缓解率13.2%(77/583),完全病理缓解率3.9%(23/583)。
- 中位总生存:主要缓解者73.4个月 vs 非主要缓解者32.2个月,P < .001。
- 阳性因素数量对应主要缓解率:0个7.5%,1个12.7%,2个16.9%,3个35.7%,P = .009。
临床怎么用
- 对于年龄<50岁、基线CA19-9<200 U/mL且接受吉西他滨作为放疗增敏剂的患者,可预期较高的主要病理缓解概率。
- 主要病理缓解与长期生存改善相关,支持将病理缓解作为预后指标。
- 需积极寻找更好的疗效预测标志物和更有效的术前方案。
局限性
- 回顾性研究设计。
- 单中心数据库。
- 术前治疗方案异质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: We previously demonstrated that a major pathologic response to preoperative therapy, defined histopathologically by the presence of less than 5% viable cancer cells in the surgical specimen, is an important prognostic factor for patients with pancreatic ductal adenocarcinoma. However, to our knowledge, the patients most likely to experience a significant response to therapy are undefined. OBJECTIVE: To identify clinical factors associated with major pathologic response in a large cohort of patients who underwent preoperative therapy and pancreatectomy for pancreatic ductal adenocarcinoma. DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of a prospectively maintained database at University of Texas MD Anderson Cancer Center. The study included 583 patients with histopathologically confirmed pancreatic ductal adenocarcinoma who received preoperative therapy prior to pancreatectomy between 1990 and 2015. EXPOSURES: Preoperative therapy consisted of systemic chemotherapy alone (n = 38; 6.5%), chemoradiation alone (n = 261; 44.8%), or both (n = 284; 48.7%) prior to pancreatoduodenectomy (n = 514; 88.2%), distal pancreatectomy (n = 62; 10.6%), or total pancreatectomy (n = 7; 1.2%). MAIN OUTCOMES AND MEASURES: Clinical variables associated with a major pathologic response (pathologic complete response or <5% residual cancer cells) were evaluated using logistic regression. RESULTS: Among all patients, the mean (SD) age was 63.7 (9.2) years, and 53.0% were men. A major pathologic response was seen in 77 patients (13.2%) including 23 (3.9%) who had a complete pathologic response. The median overall survival duration was significantly longer for patients who had a major response than for those who did not (73.4 months vs 32.2 months, P < .001). On multivariate logistic regression, only age younger than 50 years, baseline serum cancer antigen 19-9 level less than 200 U/mL, and gemcitabine as a radiosensitizer were associated with a major response. The number of these positive factors was associated with the likelihood of a major response in a stepwise fashion (0, 7.5%; 1, 12.7%; 2, 16.9%; 3, 35.7%; P = .009). CONCLUSIONS AND RELEVANCE: Although a major pathologic response occurs infrequently following preoperative therapy for pancreatic ductal adenocarcinoma, it is associated with a significantly improved prognosis. Of the patient- and treatment-related factors we analyzed, only young age, low baseline cancer antigen 19-9, and gemcitabine as a radiosensitizer were associated with a major pathologic response. Given its association with long-term survival, better predictors of response and more effective preoperative regimens should be aggressively sought.
引用
- Cloyd JM, Wang H, Egger ME, et al. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017. PMID: 28700784. doi:10.1001/jamasurg.2017.2227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。